CIK 0001326190
- Non-accelerated filer
- Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 202726770
- Phone
- +1 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $96,431
- in 4 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$96,431. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-13 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | $1.62 | $16K | 73,005 |
| 2026-11-11 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion | +18,750 | 68,677 | ||
| 2026-11-11 | WEAVER GREGORY L Chief Financial Officer | Shares withheld for taxes | −5,672 | $1.93 | $11K | 63,005 |
| 2026-11-11 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −18,750 | 37,500 | ||
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion | +14,475 | 54,306 | ||
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Shares withheld for taxes | −4,379 | $2.76 | $12K | 49,927 |
| 2026-10-01 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −14,475 | 43,425 | ||
| 2026-07-31 | WEAVER GREGORY L Chief Financial Officer | Grant or award | +1,753 | $2.41 | $4K | 39,831 |
| 2026-04-01 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | $3.15 | $31K | 38,078 |
| 2026-03-06 | WEAVER GREGORY L Chief Financial Officer | Purchase | +5,000 | $3.54 | $18K | 28,078 |
| 2026-02-26 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Stock Options (option to buy) | +259,000 | 259,000 | ||
| 2026-02-26 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Restricted Stock Units | +111,000 | 111,000 | ||
| 2025-11-11 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion | +18,750 | 28,750 | ||
| 2025-11-11 | WEAVER GREGORY L Chief Financial Officer | Shares withheld for taxes | −5,672 | $4.28 | $24K | 23,078 |
| 2025-11-11 | WEAVER GREGORY L Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −18,750 | 56,250 | ||
| 2025-10-01 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Stock Options (option to buy) | +166,800 | 166,800 | ||
| 2025-10-01 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Restricted Stock Units | +57,900 | 57,900 | ||
| 2025-03-13 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | $5.20 | $52K | 10,000 |
| 2024-11-11 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Stock Options (option to buy) | +225,000 | 225,000 | ||
| 2024-11-11 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Restricted Stock Units | +75,000 | 75,000 |
Page 1 of 1 · 20 trades